SUDEP is a sudden, unexpected, witnessed or unwitnessed, non-traumatic and non-drowning death in patients with epilepsy, with or without evidence for a seizure and excluding documented status epilepticus, in which postmortem examination does not reveal a toxicologic or anatomic cause of death [1]. “Understanding SUDEP characteristics through third-party accounts is vital, but these valuable narratives remain underutilised,” Dr Alexander Grundmann (Newcastle University, UK) observed. The opinions of friends and family of SUDEP victims have traditionally not been sought, out of fear of being inappropriate. However, their consistent message has been that they do wish to contribute to research.
The research community now sees addressing SUDEP as one of its priorities, Dr Grundmann said.
He presented the first comprehensive analysis of adult SUDEP characteristics from accounts in the SUDEP action UK epilepsy deaths register (EDR) [2]. Established in 2013, this register is a safe and secure platform for third-party reports on the death of people with (suspected) epilepsy. Included were those aged ≥15 years with a post-mortem, death certificate or narrative in keeping with SUDEP.
Of 1,056 EDR registrations, 407 met SUDEP criteria. Cases were predominantly male (59.4%) and aged 19-49 years (76.3%). “SUDEP most often occurs under the age of 30, but the oldest patient was aged 85, so the risk is never completely gone,” stressed Dr Grundmann. One of the most recognised risk factors for SUDEP is living alone, but this was not reflected in the results: 71.6% were living with family/friends. Of determinable cases, 85.9% occurred at night and 80.8% during sleep, with 63.2% found lying prone. The most common (combinations of) risk factors that were identified are shown in the analysis (see Figure).
Figure: Influence of risk factors on incidence rates of SUDEP [2]

TCS, tonic-clonic seizures
The majority (58.7%) never forgot to take medications, and 79.1% had seen a neurologist in the previous year. The majority (51.1%) had no comorbidities. SUDEP was not recorded in the death certificate in 24.9% of cases. Notably, 51.4% of reporters did not know someone could die from epilepsy. Dr Grundmann concluded: “All epilepsy patients and their relatives should be counselled on the risk of SUDEP.”
- Nashef L, et al. Epilepsia. 2012;53(2):227-33.
- Grundmann A, et al. The Epilepsy Deaths Register: Friend, family and care-giver reports of SUDEP in adults and older adolescents. OPR-083, EAN Congress 2025, 21-24 June, Helsinki, Finland.
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« Is ChatGPT helpful in diagnosing polyneuropathies? Next Article
Letter from the Editor »
« Is ChatGPT helpful in diagnosing polyneuropathies? Next Article
Letter from the Editor »
Table of Contents: EAN 2025
Featured articles
Letter from the Editor
Lecanemab in AD: not a paradigm shift, but a small step forward
Sleep
OX2R agonists are a promising causal treatment of narcolepsy
Neurologists must wake up to the importance of sleep
Infectious Diseases
Virus-specific T cells show promise in treating PML
Parkinson's disease
Encouraging results of adaptive DBS for Parkinson’s disease
Cognitive Impairment and Dementia
Dementia doubles the mortality risk 1 year after hip fracture
Lecanemab in AD: not a paradigm shift, but a small step forward
Headache and Migrane
GLP-1R agonists reduce migraine burden in obese patients
Occipital nerve stimulation is no more effective than placebo in cluster headache
Similar efficacy of anti-CGRP mAbs in short- and long-term migraine prevention
Why a good result of migraine treatment may not be good enough
Multiple Sclerosis
Rituximab does not halt progression in non-active secondary progressive MS
Real-world data confirms the effectiveness and safety of ofatumumab in MS
Comparable effectiveness and persistence of ocrelizumab and natalizumab
Muscle/Neuromuscular Disorders
Earlier add-on treatment in myasthenia gravis improves outcomes
Long-term benefits of cipa/mig in late-onset Pompe disease
Neuropathies
Is ChatGPT helpful in diagnosing polyneuropathies?
Riliprubart could be a new treatment option for CIDP
CAR T cell therapy shows promise in severe autoimmune neuropathies
Epilepsy
SUDEP is an underreported cause of death in epilepsy patients
Stroke
Significant impact of implementing thrombectomy in Spanish stroke centres
Related Articles
July 30, 2019
New compounds for MS treatment
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
